Apollo Hospitals Q4 Results 2025 | Q4 PAT Grows by 60%; ₹10/Share Dividend Declared. Know More!!

Name: Stock Advisory service In India
Brand: univest
Rating: 4.4 (197000 reviews)

Posted by : sachet | Mon Jun 02 2025

Apollo Hospitals Q4 Results 2025 | Q4 PAT Grows by 60%; ₹10/Share Dividend Declared. Know More!!

Apollo Hospitals Q4 Results 2025: One of Asia’s leading healthcare service providers, Apollo Hospitals, released its Q4 results on 30th May 2025. The health care provider reported a YoY PAT growth of 60.41% for Q4 FY25. The net profit for the period stood at ₹414 crores against ₹258 crores in Q4 FY25. The revenue from operations for the Jan-Mar 2025 quarter was ₹5,592 crores, up by 13.11% from ₹4,934 crores in the same period in FY25. Apollo Hospitals Enterprise Limited also recommended a final dividend of ₹10 per share for the financial year 2025.

Table of Contents

Apollo Hospitals Q4 Results 2025: Extracts of FY25 Financials (Consolidated Figures)

Particular	Quarter Ended		Year Ended
Particular	31 – 03 – 2025	31 – 03 – 2024	31 – 03 – 2025	31 – 03 – 2024
Revenue From Operations	₹5,592	₹4,943	₹21,974	₹19,059
Total Income	₹5,653	₹4,972	₹21,994	₹19,165
Profit Before Tax (PBT)	₹515	₹368	₹2,039	₹1,380
Profit After Tax (PAT)	₹414	₹258	₹1,505	₹935
Total Comprehensive Income	₹411	₹258	₹1,498	₹924
EPS (Basic and Diluted)	27.10	17.65	100.56	62.50

*Figures in crores, except EPS

Apollo Hospitals Q4 Results 2025 Highlights: Consolidated Figures (Q4 vs FY25)

During Q4 FY25, the PAT of Apollo Hospitals stood at ₹414 crores against ₹1,505 crores in the full FY25.
The reported PAT growth for the quarter stood at 60.14% against 60.97% in FY25.
Revenue from operations for the quarter was ₹5,592 crores, Vs ₹21,974 crores in FY25.
For the quarter ended 2025, the revenue growth stood at 13.11%, whereas in the full FY 25, revenue growth was 14.34%.
PBT for Q4 FY25 was ₹515 crores vs ₹2,039 crores in FY2025.
Reported EBITDA for the period stood at ₹769.7 crores, while EBDITA margins jumped to 13.67%.

Apollo Hospitals Share Price Performance

Share of Apollio Hospitals Enterprise Limited opened with 0.92% gains at ₹6,944 a share during the trading session on 2nd June 2025. However, the initial gains were wiped out with the shares diving to the levels of ₹6,894 around the day’s closing. Apollo Hospitals shares made a day high of ₹7,090 and a day low of ₹6,906 per share on 2nd June 2025.

Apollo Hospitals Share Price Targets

Citi has maintained a buy rating for the company with a share price target of ₹8,260. The brokerage has highlighted that the Q4 performance of Apollo hospitals was in line with estimates, while the revenue and EBIDTA growth were good at 13% and 20% respectively.

Goldman Sachs has given a ‘BUY’ rating for Apollo Hospital Shares. The price target set by the brokerage is ₹7,850. Goldman commented that the Q4 results of Apollo Hospitals fell short of its estimates. However, the brokerage believes that the successful execution of the 24/7 platform, integration of Keimed, and the addition of 3500 beds will drive shareholders’ returns.

FAQs on Apollo Hospitals Q4 Results 2025

1. What is Apollo Hospitals Q4 results?

Apollo Hospitals’ net profit grew by 60% to ₹414 crores during Q4 FY25 and 61% in FY25 to ₹1,505 crores. The revenue for the quarter ended March 2025 stood at ₹5,592 crores, up by 13.11% YoY from ₹4,943 crores in Q4 FY24.

2. What is business of Apollo Hospitals Ltd?

Apollo Hospitals Enterprise Limited is a leading healthcare service provider in Asia. It is also India’s first corporate hospital. The company offers a wide range of services in the healthcare industry, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics, and several retail health models. Apollo Hospitals also undertakes health insurance services, global projects, consultancy, medical colleges, and others.

3. What is Apollo Hospitals share price target?

Citi and Goldman Sachs have set share price targets for Apollo Hospitals at ₹8,260 and ₹7,850 per share, respectively.

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.